Advertisement

Topics

Actavis plc and Ironwood Pharmaceuticals, Inc. Company Profile

02:15 EDT 23rd September 2018 | BioPortfolio

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of other countries. Our pipeline priorities include exploring further opportunities for linaclotide, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to address patient needs across the upper and lower gastrointestinal tract. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. Connect with us at www.ironwoodpharma.com or on Twitter at www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.


News Articles [436 Associated News Articles listed on BioPortfolio]

Ironwood Pharmaceuticals to divide into two companies

US-based biotech company Ironwood Pharmaceuticals has revealed plans to split into two independent, publicly traded companies, Ironwood and R&D. After...Read More... The post Ironwood Pharmaceutic...

Ironwood Pharmaceuticals to Separate into Two Companies

Ironwood Pharmaceuticals will split into two independent companies, Ironwood and what is currently being dubbed R&D Co.

Ironwood Pharma to Split in Two, Forming New Rare Disease Biz

Ironwood Pharmaceuticals (NASDAQ: IRWD) is making the unusual move of splitting up into two separate, publicly traded companies. One, which will keep the Ironwood name, will focus on selling its three...

Ironwood Pharmaceutical To Separate Into Two Independent Companies

NewsIronwood, a commercial biotech company, today announced that its Board of Directors has authorized an intent to separate into two independent, publicly traded companies (Ironwood and “R&D Co.”...

Ironwood begins two Phase III trials of IW-3718

Ironwood Pharmaceuticals has commenced two Phase III clinical trials to examine the safety and efficacy of IW-3718 in patients with...Read More... The post Ironwood begins two Phase III trials of IW-3...

Ironwood returns US Zurampic rights to AstraZeneca, announces operational cuts

Ironwood Pharmaceuticals has revealed that it has taken the decision to hand the rights for gout therapy Zurampic (lesinurad) back to AstraZeneca, terminating an agreement between the two firms that w...

FDA fast-tracks Ironwood's heart failure candidate

Ironwood Pharmaceuticals' IW-1973, or praliciguat, indicated to treat patients with heart failure with preserved ejection fra -More- 

FDA gives orphan status to Ironwood's sickle cell disease drug

Ironwood Pharmaceuticals' IW-1701, or olinciguat, was given orphan drug designation by the FDA.  -More- 

PubMed Articles [143 Associated PubMed Articles listed on BioPortfolio]

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Post-production handling and administration of protein pharmaceuticals and potential instability issues.

The safety and efficacy of protein pharmaceuticals depend not only on biological activity, but also on purity levels. Impurities may be process related due to limitations in manufacturing, or product ...

Effects of pharmaceuticals on microbial communities and activity of soil enzymes in mesocosm-scale constructed wetlands.

Cyperus alternifolius based mesocosm-scale constructed wetland was employed to remove pharmaceuticals. We investigated the microbial community composition using phosphor lipid fatty acids (PFLAs) anal...

Clinical Trials [232 Associated Clinical Trials listed on BioPortfolio]

Clinical Endpoint Study of Ivermectin 0.5% Lotion

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Lotion 0.5% (Actavis Laborato...

A Relative Bioavailability Study of 50 mg Venlafaxine Hydrochloride Tablets Under Fed Conditions

The purpose of this study to assess the single-dose relative bioavailability of Actavis Group hf 50 mg venlafaxine hydrochloride tablets with Wyeth Pharmaceuticals (Effexor®) 50 mg venlaf...

A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Non-Fasting Conditions

To compare the relative bioavailability of oxycodone HCl 5 mg / ibuprofen 400 mg tablets (Actavis Elizabeth LLC, Lot No. PI-1565) with that of COMBONOX® tablets (Forest Pharmaceuticals, I...

A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Fasting Conditions

To compare the relative bioavailability of oxycodone HCl 5 mg / ibuprofen 400 mg tablets (Actavis Elizabeth LLC, Lot No. PI-1565) with that of COMBONOX® tablets (Forest Pharmaceuticals, I...

A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-Fasting Conditions

The purpose of this study is to compare the relative bioavailability of Propranolol Hydrochloride Extended Release Capsules 160 mg (Actavis) with that of INDERAL® LA 160 mg Capsules (Wyet...

Companies [1336 Associated Companies listed on BioPortfolio]

Actavis Inc.

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has ...

Almirall, S.A. and Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agon...

Forest Laboratories, Inc. & Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agon...

Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agonist, is...

Ironwood Pharmaceuticals, Inc. and Almirall

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Ironwood is located in Cambridge, Mass. ...

More Information about "Actavis plc and Ironwood Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Actavis plc and Ironwood Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Actavis plc and Ironwood Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Actavis plc and Ironwood Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Actavis plc and Ironwood Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Actavis plc and Ironwood Pharmaceuticals, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record